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Abstract.
BACKGROUND: Recent advances in medical care have increased life expectancy and improved the quality of life for people
with Down syndrome (DS). These advances are the result of both pre-clinical and clinical research but much about DS is
still poorly understood. In 2020, the NIH announced their plan to update their DS research plan and requested input from the
scientific and advocacy community.
OBJECTIVE: The National Down Syndrome Society (NDSS) and the LuMind IDSC Foundation worked together with
scientific and medical experts to develop recommendations for the NIH research plan.
METHODS: NDSS and LuMind IDSC assembled over 50 experts across multiple disciplines and organized them in eleven
working groups focused on specific issues for people with DS.
RESULTS: This review article summarizes the research gaps and recommendations that have the potential to improve the
health and quality of life for people with DS within the next decade.
CONCLUSIONS: This review highlights many of the scientific gaps that exist in DS research. Based on these gaps,
a multidisciplinary group of DS experts has made recommendations to advance DS research. This paper may also aid
policymakers and the DS community to build a comprehensive national DS research strategy.
Keywords: Down syndrome, intellectual disability, cognitive development, autism spectrum disorder, obstructive sleep apnea,
congenital heart disease, obesity, muscle hypotonia, leukemia, autoimmune disease, periodontitis, and Alzheimer’s disease
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1. Introduction
Down syndrome (DS) is the most common chromosomal disorder in humans, affecting about one
of every 675 births [1]. Underlying the diverse spectrum of phenotypes seen in people with DS is an
extra copy of chromosome 21 (Chr21), or trisomy 21 (T21), which results in overexpression of many
genes and changes in the proteome [2]. It is associated with intellectual disability, facial dysmorphism,
short stature, and poor muscle tone or loose joints. There is also an increased risk of Alzheimer’s
disease (AD), childhood leukemia, congenital heart disease, sleep dysfunction, metabolic disorders,
autoimmune disorders such as thyroid disease, Type 1 diabetes, celiac disease, rheumatoid arthritis,
and developmental disorders such as autism spectrum disorder (ASD) [3]. At the same time, however, individuals with DS have a decreased risk of developing atherosclerosis and certain adult cancers
[4, 5]. With improved healthcare, people with DS are now living longer, with a life expectancy of > 55
years of age compared to just 25 years of age in the 1980’s. It is estimated that there are 210,000 people
with DS in the United States and 40% are over the age of 30 years old [6].
Research to better understand DS across clinical, pathological, genetic, cellular, and molecular
domains is essential to develop appropriate interventions to promote health and wellness across the
lifespan. Such research has flourished in recent years, driven by technological innovations, emerging
international collaborations, increased funding, and worldwide advocacy efforts. With the hope of
leveraging the growing momentum to support DS research, two major DS organization, the National
Down Syndrome Society (NDSS) and the LuMind IDSC Foundation crafted recommendations for a
research strategy focused on the quality of life and care priorities of people with DS by 2030. The
impetus for this effort was the US National Institutes of Health (NIH) RFI (Request for Information,
Notice Number: NOT-HD-20-013) to update NIH research plans on Down syndrome in 2020. The
NDSS and LuMind IDSC worked together with the scientific community to develop recommendations
for the NIH. In addition, other DS organizations contributed, including the Jérôme Lejeune Foundation
and the National Task Group on Intellectual Disabilities and Dementia Practices.
2. Methods
DS research is broad in scope and engages a wide spectrum of scientific and health care disciplines.
To accomplish the goals of the project, eleven working groups made up of experts across multiple disciplines were established to focus on specific issues of special concern to people with DS. These topical
groups addressed cognitive development; autism spectrum and behavioral disorders; impaired speech,
language, hearing, and vision; heart and vascular disorders; sleep and respiratory problems; obesity,
metabolic and musculoskeletal problems; cancer; immune system disorders; dental and oral health;
and AD and aging. The eleventh working group focused on the importance of community engagement
in all aspects of DS research to ensure that the strategy developed through this process is driven by
and resonates with the DS community. Members of the community engagement working group came
from a variety of organizations including LuMind IDSC, NDSS, local Down syndrome affiliates, and
GiGi’s Playhouse. Important contributions were also made by caregivers and self-advocates to ensure
that the DS community had input into the recommendations.
Workgroup members met via teleconference for over four months to discuss the state of the science
in their respective topic areas, with plans to distill their findings into a research agenda for the next
decade. In April 2020, a two-day meeting was held in a virtual format due to the COVID-19 pandemic.
The virtual meeting stimulated discussion that enabled top researchers in the field to share information,
look for areas of overlap across workgroup topics, and identify unaddressed needs and research gaps.
This paper summarizes areas of medical need for people with DS that have been understudied, unfunded
or underfunded historically by federal and state agencies and foundations. The article is intended to
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serve as a call to action to the entire biomedical research community, to act as a catalyst for advocacy
in research on DS, and to give research on DS the attention and funding that people with DS deserve.
3. Cognitive development and independence
To understand the effects of T21 on the development and function of the brain, three main questions
were identified as areas to prioritize: 1) What brain regions and cell types are affected and what is the
relationship of these effects to cognitive phenotypes? 2) When do deficits arise; are they the consequence of neurodevelopmental changes or functional changes in neural cells; and are they preventable
or potentially correctable? 3) What are the underlying mechanisms by which T21 causes cognitive
deficits? By understanding the answers to these questions at cellular and molecular levels, it may be
possible to identify therapeutic targets and at what point targeting them might prove useful to positively
affect cognition.
Human studies provide information about how brain anatomy and structure change across the lifespan
and are also critical for genomic analyses. Anatomical studies indicate that DS is associated with a
smaller cortex and cerebellum, with reductions in the number of neurons but increases in numbers
of glia [7–9]. Neurons have dendritic spine defects and altered synaptic plasticity while glial defects
indicate altered myelination [10, 11].
Deficits have also been reported in the function of synapses, mitochondria, and endosomes; and cell
stress pathways appear to be activated. Several human Chr21 (HSA21) genes have been implicated in
development, including some that regulate neural development and developmental signaling pathways
and others involved in multiple stress mechanisms. Many more HSA21 genes have not been well
studied and gene interaction effects must also be considered. In addition, T21 affects the expression
of genes throughout the genome and so consideration of molecular and cellular pathways, metabolic
and immune defects, and environmental factors may also impact brain function in DS.
Translating these anatomical and neural findings has helped refine what aspects of cognition are
targeted in studies of individuals with Down syndrome. Specific constructs of executive functioning,
learning and memory, and working memory are being targeted with an emphasis on determining the
best measures for assessing these constructs and change in these constructs [12–16]. Further attention
to the measurement of cognitive constructs has focused on social cognition, emotion recognition,
and evaluating cognitive batteries [17–28]. The downstream impact of these cognitive constructs on
functional outcomes has primarily considered children with DS, understanding the impact on formal
education, and adaptive daily living skills [29–35]. Given a pattern of findings linking cognitive skills to
fine and gross motor control [36–41], preliminary small pilot trials to improve cognitive outcomes have
more recently focused on the impact of physical activity interventions [42–44]. Both behavioral and
pharmaceutical interventions are also being piloted to improve cognitive outcomes in individuals with
DS [44–51]. Research on individuals with DS has frequently focused on between-group differences in
comparison to other individuals with intellectual disability [52–57]. This focus has helped identify the
unique cognitive phenotype common in individuals with DS. Group differences have also elucidated the
impact of comorbid medical conditions on cognitive outcomes for individuals with DS, specifically
cognitive outcomes for children with DS with or without comorbid congenital heart defects, sleep
challenges including obstructive sleep apnea (OSA), and autism spectrum disorder [58–75].
Cognition may have impacts on other aspects of life such as independence. For individuals with
DS, the degree of intellectual disability is one possible factor that may restrict independence. Studies
show that speech ability and training, and access to a medical home can improve independence for
individuals with DS [76, 77]. Measures of adaptive skills and surveys show that independence decreases
with age in DS, which is likely multifactorial and presumably related to increasing risk for dementia [78,
79]. Drawing from studies of individuals with intellectual disability, speech independence, autonomy,
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and self-management predict independence, while low physical fitness and changes in ADLs may
indicate decreasing independence [80–82]. Importantly, independence for individuals with intellectual
disability can be promoted through interventions including video prompts, video self-modeling, staff
training, and the use of technology and remote support services [81, 83–85].
While studies in humans are the gold standard, two types of research models are valuable to address
cellular and molecular aspects of T21 in the brain: trisomic mouse models, and human T21 induced
pluripotent stem cells (iPSCs) [86]. Human stem cell research enables investigations of T21 in the
human genetic background at the molecular and cellular levels and enables mechanistic investigation.
Current understanding of DS neurobiology is derived largely from mouse studies (e.g. Ts65Dn, Tc1)
[87, 88]. Support for new mouse models that will minimize non-HSA21 genetic changes are needed
[89]. In addition, it is becoming clear that aspects of gene regulation and brain development and function
differ between mice and humans, so integrating information from these complementary models is
essential to understand trisomy neurobiology and development [90–92].
Many drug candidates tested are reported to improve learning and memory in DS mouse models;
however, the relevance of these findings to humans remains uncertain. Human cell and organoid models
may be useful for testing drugs that target cell-based pathologies. Biomarkers – including functional
measures such as functional magnetic resonance imaging (fMRI), electroencephalography (EEG), and
functional near-infrared spectroscopy (fNIRS) - are clearly needed to advance drug development.

4. Cognitive development and independence research gaps
To gain a better understanding of cognitive deficits associated with DS, new preclinical models of
cognition are needed to help establish the stage of cognitive development that could be amenable to
improvement. Therefore, inducible models of trisomy silencing or specific gene silencing should be
developed. In addition, mouse studies are needed that can establish a correlation between changes in
synaptic plasticity with learning and memory deficits. Finally, new DS models should reflect human
physiology and genetic heterogeneity (e.g. outbred backgrounds).
More support of human cognition research in DS is also needed. To establish the link between
cognitive performance and underlying brain structure, neurocognitive tools such as fMRI, EEG, and
transcranial magnetic stimulation (TMS) should be utilized. Reliable and valid clinical outcome measures across the lifespan should be developed, as well as studies on the natural development of these
associated constructs, to enable longitudinal studies and to advance clinical trials [12, 15]. It is important
to support research focused on the wide heterogeneity of cognitive function across the DS population,
including the effects of medical conditions (e.g. Attention-Deficit Hyperactivity Disorder (ADHD),
ASD, anxiety, Acute Myelocytic Leukemia (AML), Acute Lymphocytic Leukemia (ALL)) in order
to identify those individuals who will benefit from a particular intervention and who would be appropriate for inclusion in a clinical trial. To better understand all the factors that impact cognitive skills
and meaningful functional outcomes, it is important to establish strong collaboration across behavioral
disciplines.
There is need to include assessments of independence when studying human cognition. To understand the factors that contribute most to independence, additional research on the natural history of
independence in people with DS is needed. Specifically, consideration should be given to what aspects
are most meaningful to an individual with DS and caregivers, how to measure independence reliably
and validly, and how to modify those factors. Successful interventions used in individuals with ID can
guide implementation and study in individuals with DS. Large, multi-site, longitudinal studies could
evaluate human cognition and independence simultaneously to connect the lessons learned from basic
science to clinical significance; with the ultimate goal of improving independence.
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5. Behavior and autism spectrum disorder
The prevalence of coexisting psychiatric or serious maladaptive behaviors in children and adolescents
with DS is high and the consequences on education, family functioning, and socialization substantial.
It has been reported that coexisting neurobehavioral and psychiatric disorders in those with DS range
from 18 to 38% [93]. In a Swedish population-based study of children and adolescents with DS,
42% were diagnosed with ASD and 34% with ADHD [94], with the severity of ASD but not ADHD
positively associated with the level of intellectual disability [95]. Other studies have found similar rates
of ASD and behavioral symptoms in children with DS [96].
Some adolescents and young adults with DS also present with progressive and sometimes rapid
cognitive deterioration or regression, which may dramatically impair independence and autonomy
[97, 98]. A minority of individuals with DS experience worsening autistic characteristics that progress
to a dementia-like state in what has been called Down syndrome disintegrative disorder (DSDD) [99,
100]. The causes of regression and DSDD remain unclear, but may be associated with depression,
hypothyroidism, autoimmune disorders, OSA, and/or subclinical epilepsy. One small study, which
hypothesized an immune-related etiology, demonstrated significant improvements following treatment
with immunotherapy [101].
6. Gaps in behavior and ASD research
Population-based normative data on maladaptive behaviors and psychiatric syndromes across the
lifespan in DS are needed from studies with large and diverse cohorts. In addition, population-based
studies are needed to evaluate the associations between ADHD, ASD, anxiety, depression, movement
disorders, seizure disorders, and sleep disturbances. People with DS should be included in clinical
trials of emerging therapies (e.g. novel biologics, anti-immune, anti-inflammatory, GABA/glutamate,
and cell-based therapies) for autism and behavioral disorders. However, validated diagnostic and
outcome measures need to be developed in order to assess behavioral disorders and autism for the
DS population. In addition, neuroimaging and neurophysiology studies of behavioral disorders and
ASD should be conducted in people with DS. Finally, there is a shortage of trained providers and
researchers knowledgeable about DS. This has had a negative impact on advancing understanding
of behavioral and psychiatric disorders in DS. Additional support for training fellowships in DS is
needed.
7. Communication, vision, and hearing
A variety of structural and functional vision, hearing, and communication deficits are associated
with DS, as well as other anomalies of the auditory/vestibular system. Variation in these structures and
functions can be influenced by other aspects of the behavioral phenotype associated with DS. Taken
together, these problems can interfere with the development and maintenance of communication skills
critical to reading and oral language.
7.1. Communication disorders in DS
Difficulties with communication often occur in individuals with intellectual disability, but people
with DS are 2.6 times more likely to have moderate communication difficulties and 1.9 times more
likely to have severe communication difficulties than people with intellectual disability not associated
with this syndrome [102]. It is important to understand the reasons why many individuals with DS have
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lifelong problems with oral and written communication. Individuals with DS often exhibit delays in
language development, with greater delays in expressive than receptive language [103]. Difficulties with
language development are demonstrated from very early in development and continue into adulthood,
with delays observed in the earliest stages of prelinguistic communication. These delays continue
into the adolescent and young adult years, including the use of complex language for participation
and social interaction in everyday life [104]. Speech is the main form of communication in 97%
of all people with DS and therefore is critical to social interactions of all kinds. Reduced speech
intelligibility is common in children and adults with DS [105, 106], resulting from a combination
of motor impairments, phonological delay or disorder, hearing loss, and craniofacial and laryngeal
dysmorphology [107]. Speech intelligibility and language delays are major concerns for children with
DS and their families. But many adults with DS also experience lifelong difficulty with the intelligibility
of their speech [108]. Nonetheless, children with DS do demonstrate gains in language development
and a pattern of relative strengths and weaknesses in this domain, including more substantial delays in
expressive syntax than in expressive vocabulary, for example [109]. Recent studies have also shown
that verb usage is particularly limited in people with DS, leading to less language complexity and
poorer discourse skills [110]. However, there are developmental changes in this profile over time [103,
104, 111]. For example, receptive and expressive vocabulary have been shown to improve during early
adolescence but to decline in late adolescence and early adulthood, perhaps foreshadowing the later
more dramatic declines associated with early onset Alzheimer’s disease. Given nuances in language for
people with DS, treatment and intervention for language impairments in this population must consider
both the language phenotype and overall behavioral phenotype [103, 104, 112], leveraging language
strengths to support treatment and intervention efforts.
7.2. Gaps in communication research
Research focused on the development of assessments and new interventions for improved communication for individuals with DS across the lifespan is needed. Validated, standardized measures
of language may be used but may need modification for extensive testing in the DS population. The
development of DS-specific language norms is needed, with the incorporation of other psychometric
features, especially those relevant for use as outcome measures in treatment studies, including clinical trials. Studies that can distinguish the effects of motor speech disorders from effects caused by
anatomical dysmorphology are needed to develop tools for clinical assessments and to facilitate the
development of effective interventions across the lifespan. More and larger studies assessing the efficacy of high-intensity speech interventions in young children are needed. There is also a need to more
fully understand the ways in which the social and linguistic environment supports or hinders language
development in order to identify potential pathways and mechanisms for intervention. Lastly, there
is a need for studies on language and communication in adulthood to understand the trajectory of
improvement and possible age-related decline.
7.3. Vision disorders in DS
Ocular disorders are common in DS with reduced visual acuity observed even with refractive corrections. Specific impairments in vision include elevated refractive errors, strabismus, nystagmus, and
corneal abnormalities all of which may contribute in part to the reduced visual acuity observed in
DS [113]. These disorders are associated with abnormal visual developmental and possibly structural
differences in the retina, cornea, and optic nerve [114–117]. Improved clinical strategies are needed to
address visual deficits in this group, as most individuals do not achieve normal visual performance with
standard refractions. Early intervention is likely to aid visual development for children with DS, but
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structural deficits in ocular tissues, such as those commonly observed in the cornea, may progressively
worsen in later years, leading to additional losses in vision quality.
7.4. Gaps in vision research
A greater understanding is needed regarding the causes of reduced visual acuity, e.g., the contributions of retinal, corneal, and neural abnormalities. There is also a need to expand studies of the impact
of optimized refractive correction on visual outcomes to younger children. Longitudinal studies with
cohorts large enough to achieve statically meaningful results are needed to understand the progression
of structural changes in the ocular system and correlations with visual outcomes across the lifespan.
7.5. Hearing loss and vestibular problems in DS
Hearing loss is common in children and adults with DS. The incidence of hearing loss in neonates
and infants with DS is between 15% and 30% [118, 119]; between 25% and 85% in children and
adolescents [120, 121]; and between 50% and 75% in adults [122, 123]. While most hearing loss in DS
is associated with otitis media with effusion, mixed conductive-sensorineural loss is also common and
is usually secondary to inner ear malformations [124], which may also cause symptoms of vestibular
dysfunction such as dizziness, vertigo, and balance disorders. Anomalies in the auditory system in
DS have been reported for the outer ear, middle ear, and inner ear [125–131]. Other factors that may
contribute to vestibular dysfunction in DS include: hypotonicity, joint laxity, decreased deep tendon
reflexes and delays in reaction timing, and equilibrium reactions. The vestibular system works with
other senses such as vision and proprioception to maintain balance and motor coordination.
7.6. Gaps in hearing loss and vestibular function research
More research on the detection and treatment of hearing loss across the lifespan of individuals with
DS is needed. Assessment and detection measures are needed that account for developmental and
aging effects as well as structural differences that may be present. Research on strategies to increase
the use of hearing aids among adults with DS who has hearing loss also is needed. There is evidence
that DS-AD is sometimes misdiagnosed since the symptoms observed may actually be due to hearing
impairment or other sensory deficits [132]. Hearing loss may also be a contributing factor given that it
is more frequent among adults with DS and co-morbid dementia [133]. More research on the diagnosis
of hearing impairment in adults with DS is needed.
8. Heart and vascular
Congenital heart disease (CHD) represents one of the cardinal features of DS, affecting more than
40 percent of infants with T21 [134]. Multiple subtypes are seen, including complete atrioventricular
septal defects (AVSD), ventricular septal defect, atrial septal defect, partial atrioventricular septal
defect, Tetralogy of Fallot, and patent ductus arteriosus; and the presence of multiple anomalies is
common [135–139]. Early diagnosis improved surgical outcomes, and better perioperative care have
resulted in significant increases in survival over the past two decades, contributing to the improved
longevity for people with DS.
Trisomy 21 clearly significantly increases the risk for AVSD and other heart defects but is not
sufficient to cause CHD. It was originally hypothesized that T21 unmasks a common susceptibility
variant that explained the hugely increased in risk for AVSD observed in DS. Using a genome-wide
association study approach, no evidence for this hypothesis was obtained [140–142]. Instead, current
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findings suggest an increased burden of rare variants as contributing to risk for AVSD in DS, some of
which overlap with those found for non-syndromic CHD (nsCHD). Such variants (including singlenucleotide variants, microRNAs, and copy number variants) are not restricted to chromosome 21, but
found throughout the genome [140, 141, 143–145]. Thus, the modified hypothesis states that having an
extra Chr21 predisposes to abnormal heart development, but additional rare variants or environmental
triggers are required to exceed a susceptibilty threshold to lead to CHD. Support for this hypothesis
and proof-of-principle has been provided by the Ts65Dn mouse model [146, 147]. Evidence for altered
pathways include the ciliome, Notch signaling, VEGF-A and folate/homocysteine metabolism [144,
145, 148].
In addition to CHD, individuals with DS often experience other cardiovascular problems including
cardiac arrhythmia, pulmonary hypertension, and sleep apnea. A higher risk of cerebrovascular events
including stroke and transient ischemic attack is also seen, particularly in women [149]. Immune
dysfunction and thyroid dysfunction – both prominent in DS –may also affect cardiovascular function;
and extra-cardiac comorbidities such as differences in vascular resistance and arterial stiffness may
contribute to cardiovascular dysfunction. Alterations in heart rate variability and blood pressure in the
low normal range are also relatively common in DS and may reflect autonomic dysfunction [150]. The
consequences of lower blood pressure and heart rate in DS over the lifespan are poorly understood, as
is the effect of exercise on autonomic function. The Ts65Dn mouse model also demonstrates reduced
blood pressure and heart rate variability alterations from wild-type mice, suggesting this model could
be used to explore mechanistic changes in cardiovascular function across the lifespan in DS [151].
Moyamoya disease may also occur in people with DS [152] and contributes to increased stroke risk
over the lifespan, particularly with those who have blood pressure in a higher, but normal range [153].
9. Heart and vascular disease research gaps
The genetic factors and dysregulated pathways in DS-associated CHD are just beginning to be identified. The roles of nuclear and mitochondrial genes and their possible interactions with HSA21 genes
have yet to be determined. Research integrating transcriptomic, metabolomic, proteomic and other omic approaches should be applied to these knowledge gaps. In addition, epigenomic approaches could
facilitate identification of environmental exposures associated with CHD. The integration of -omics
data could help identify underlying molecular mechanisms, help define genotypes and phenotypes
which could lead to prevention and novel treatments. From the clinical and epidemiological research
perspective, larger sample cohorts with well-defined heart phenotypes (cardiac and extra-cardiac) are
needed to define genotype / phenotype correlations in DS-associated CHD. Complementing these
studies with model systems is essential to understand genotype functions and their interactions with
the environment.
More clinical research is needed to better understand cardiovascular disease in DS. For example,
there is a need to advance understanding of the surgical and postoperative care needs of children
with DS and CHD. The early detection of Moyamoya disease is essential for better outcomes but this
will require a better understanding of early risk factors and the development of novel biomarkers.
The role of lifestyle factors such as sedentary lifestyle and exercise on cardiovascular function in
individuals with DS is not well understood. There is early evidence that increasing exercise, even
passive exercise, may also have positive effects on cognition and learning [44, 154]. One issue that
needs to be addressed to advance clinical research in DS is the issue of control groups. Proper controls
are essential for cardiovascular research in DS, however, there are many different types of controls
utilized (heart rate controls, intellectual disability without DS controls, BMI controls, activity level
controls), which complicates interpretation of data from these studies. The field should address this
issue and build consensus around a single type of DS control.
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10. Sleep and respiratory
Individuals with DS are prone to develop OSA due to a combination of anatomic and neuromotor
factors, such as midfacial hypoplasia, macroglossia, tracheal and laryngeal abnormalities, and hypotonia [155, 156]. With aging, the prevalence of OSA increases but it remains frequently underdiagnosed.
Untreated sleep disorders such as OSA may contribute to worse cognitive function and accelerate
cognitive decline [45, 46, 47]. Other respiratory problems including increased risk of infection are
common in children and adults with DS due to a combination of the mentioned anatomical and functional abnormalities, immune dysfunction, and cardiac problems [157, 158]. For example, respiratory
syncytial virus (RSV) infection is particularly prevalent and associated with high morbidity and mortality in infants and children with DS [159]. Dysphagia, also common in DS, increases the risk of
aspiration and recurrent pneumonia [160].
Children with DS also have an increased risk for developing multifactorial pulmonary hypertension [161] associated with hypoxemia, OSA, pulmonary hypoplasia, increased pulmonary vascular
resistance, and increased hemodynamic stress. The sub-group of children with DS and CHD are at
particularly high risk of developing pulmonary hypertension, but it can also be a consequence of respiratory distress syndrome [162]. Lower airway anomalies such as hypoplasia of the alveoli and other
more distal structures have also been reported [163].
11. Gaps in sleep and respiratory research
Despite previous sleep research, normative data on sleep patterns in DS are still lacking. In children and adults with DS, research is needed to evaluate the association of a characteristic DS sleep
phenotypes, i.e. reduced sleep efficiency, decreased rapid-eye movement (REM) sleep, and increased
slow-wave sleep (SWS, also called non-rapid-eye-movement 3 (NREM3 or N3) sleep), with learning
and behavioral difficulties in the context of baseline neurocognitive impairment.
Neurocognitive studies to evaluate the impact of sleep disturbances in adults with DS and its relationship to cognition, behavior, and quality of life are needed. Indeed, it is important to prospectively
assess the impact of sleep disturbances on cognitive impairment and progression to dementia in adults
with DS. Objective sleep evaluation methods and a DS-specific cognitive battery are needed to properly evaluate baseline relationships and intervention outcomes. More research is required on circadian
rhythm disruptions in people with DS. Finally, the design and validation of new sleep questionnaires
and simple at-home devices to screen for sleep disorders are needed.
Pulmonary hypertension is a significant cause of morbidity in children and infants with DS. More
research is needed to distinguish the clinical and molecular pulmonary hypertension phenotypes in DS
compared to children without DS. In addition, non-invasive airway evaluation guidelines for children
with DS that incorporate multidisciplinary aerodigestive programs are needed.
12. Musculoskeletal, metabolic factors, and obesity
Past research findings indicate that individuals with DS across the lifespan are at high risk for
musculoskeletal issues and metabolic disorders such as obesity and Type 2 diabetes [164, 165]. The
genetic and molecular mechanisms that underlie musculoskeletal and metabolic dysfunction in DS
remain unclear. T21 has been associated with altered insulin secretion, impaired hepatic glucose
metabolism, and altered insulin sensitivity in muscle. Autonomic dysfunction with altered peripheral
blood flow to muscle may affect blood distribution to the muscle and build-up of toxins, which may
lower the pain threshold and tolerance for physical activity. Research in both humans with DS and DS
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mouse models has identified changes in metabolism related to obesity, inflammation, mitochondrial
function, immunity, insulin resistance, and glucose tolerance [166].
Individuals with DS across the lifespan are at higher risk to be overweight and obese compared
to the general population [167–170]. The possible determinants of increased weight and obesity in
individuals with DS include low resting metabolic rate, low physical activity levels, and unhealthy
dietary behaviors [168, 171–173]. Obesity appears to have adverse health outcomes among individuals
with DS such as dyslipidemia, hyperinsulinemia, OSA, and gait problems [168, 174–178].
Musculoskeletal problems associated with DS include muscle hypotonia and joint laxity, both of
which can cause ambulation difficulties and other functional impairments [164]. Moreover, these problems may contribute to reduced physical activity, increased levels of obesity [168], and an elevated risk
of many disorders including heart disease, Type 2 diabetes, cancer, and osteoporosis [179]. Individuals
with DS across the lifespan have very low physical fitness and physical activity levels [180–184]; these
attributes may be either causes or outcomes of musculoskeletal and metabolic issues or bidirectional
relationships may be at play. Certainly, improving the physical activity and physical fitness levels of
individuals with DS may positively impact their health and functional profiles.
There are ongoing international efforts to better understand metabolic dysregulation in DS. The
Gene Overdosage and comorbidities during the early lifetime in Down syndrome (GO-DS21) project
recently launched in the European Union to explore metabolism and metabolomics in DS.
13. Gaps in musculoskeletal and metabolic research
Longitudinal studies on muscle development and weight changes across the lifespan in DS are
needed to explore differences between people with DS and the general population. These studies should
evaluate the development of obesity across the lifespan, delineate its causes and clinical impact, and
test interventions for reducing obesity in individuals with DS. Hypotonia is very common in DS but it
is not well understood. Research on the genetic and biochemical basis of hypotonia including the role
of mitochondrial alterations is needed to clarify the etiology of the condition. In addition, the effect of
impaired autonomic function on cardiovascular fitness is not well understood and needs more research.
There have been a few small physical activity intervention trials in DS [185–187]. More and larger
trials are needed to test the effects of physical activity as an intervention on a range of health outcomes
and the modifications that may be needed to implement such interventions in the DS population.
14. Cancer
Although there is no difference in the overall incidence of cancer among the DS population compared
to the non-DS population, DS is associated with a decreased incidence of solid tumors and an increased
incidence of hematological malignancies, specifically acute leukemias [5, 188].
Compared to the non-DS population, individuals with DS are 500 times more likely to be diagnosed with acute myeloid leukemia (ML-DS) and 20 times more likely to be diagnosed with acute
lymphoblastic leukemia (DS-ALL). Survival outcomes for ML-DS are superior to the general population, with event-free survival rates ranging from 80–100%. Clinical trials are focused on optimizing
chemotherapy to reduce toxicity while maintaining survival outcomes [189, 190]. Outcomes for patients
with DS-ALL are inferior to the general population and patients with DS treated for ALL have excess
treatment toxicity and treatment morbidity. Novel approaches to treat DS-ALL are needed to improve
survival and decrease treatment morbidity [191, 192]. Factors that contribute to variability in treatment
response and outcomes are not fully understood but may include differences in the genetics and biology
of DS-leukemia as well as those related to the DS-phenotype (i.e., gene dose effect from T21).
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The risk for DS-leukemia (ML-DS and DS-ALL) is greatest during early childhood (ages 1–4),
a critical neurodevelopmental period. Treatment for DS-leukemia (DS-ALL in particular) involves
central nervous system (CNS)-directed chemotherapy. Treatment for DS-ALL is 2.5 – 3 years in
duration with extended periods of immunocompromise resulting in missed opportunities for social
interaction, early intervention and education services that support developmental gains throughout
childhood. It has been well-established that survivors of childhood ALL without DS have a higher risk of
neurocognitive deficits [193, 194]. Given the preexisting cognitive vulnerability in DS, the cumulative
impact of CNS-directed treatment and missed community participation may add to neurocognitive
deficits. Compared to survivors of leukemia without DS, survivors of DS-leukemia may be at increased
risk for treatment late effects and poorer quality of life [195–197]. Improved understanding of the
impact of leukemia and its therapy on neurodevelopmental, health, and quality of life outcomes has
the potential to inform modifications to treatment, approaches to supportive care during therapy, and
interventions to ameliorate side effects.
15. Gaps in cancer
Improved characterization of clinical, biological, and genetic phenotype in DS-leukemia is needed
to identify therapeutic targets and further refine treatment. A better understanding of DS-leukemia
genomics may also have implications for surveillance and diagnosis. Evidence-based approaches to
supportive care, improved assessment and management of side effects and toxicities in DS leukemia
needs to be developed. Longitudinal studies of neurodevelopmental, health, and quality of life outcomes
in cancer survivors beginning during therapy, in order to inform supportive care and interventions to
ameliorate problems are also needed.
15.1. Immune system disorders
The architecture of the immune system is significantly altered in people with DS, with common
findings of leukopenia, lower B cell frequencies, and pro-inflammatory shifts including increased
proportion of memory T cells, pro-inflammatory T cell subsets, and pro-inflammatory cytokineproducing cells [198, 199]. Consistent with this pro-inflammatory milieu, people with DS exhibit
a highly increased risk of developing autoimmune diseases including thyroid disease, Type 1 diabetes,
celiac disease, rheumatoid arthritis, systemic lupus erythematosus, and atopy. Paradoxically despite
this augmented immune response, individuals with DS are more susceptible to infectious disease, which
account for 50% of deaths in individuals with DS [3]. This includes increased mortality secondary
to RSV and now to COVID-19 infections. [198–204]. Additionally, these diseases may manifest at
earlier ages and greater severity in people with DS.
16. Gaps in immune system disorders research
Critical gaps exist in our understanding of the specific facets of immune dysregulation and the
underlying mechanistic pathways, which drive predisposition to autoimmunity and poor outcomes
with infection. Research is needed to clarify which existing therapeutics are most effective for people
with DS and to prioritize targets for novel therapeutics. Although candidate genes on Chr21, including
IFNAR1/2 and DYRK1A, have been identified, the role of most HSA21 genes is unclear. Additionally,
studies showing that T21 can impact transcription on other chromosomes suggests that the scope of
this research will likely extend beyond Chr21. Because the risk of autoimmunity increases with age,
longitudinal studies are also needed with genomic confirmation of full or partial trisomy of genes
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associated with immunity. Sampling prior to developing autoimmunity is necessary to allow us to
better understand who is at higher risk, and how that risk might be mitigated. Genotyping for known
autoimmunity-associated polymorphisms will help us better understand how T21 modulates single
nucleotide polymorphisms (SNP)-associated risk. Similar SNPs on T21 that are normally rendered
silent might exert their effect due to gene dosage, but also perhaps due to overall perturbed clinical
state. Linked clinical metadata, particularly the severity of autoimmunity and response to specific
therapeutics, will enhance translational significance of this work. To better understand the role of
thymic dysfunction in autoimmunity, studies should assess the consequences of thymectomy (e.g.
on the differentiation of T cells into subsets and the production of self-reactive T cells) in children
with CHD who undergo this procedure to provide surgical access as part of their cardiac surgery. As
the immune system penetrates all organ systems, it is important to better understand how the immune
system connects to dermatological, neurological, and gastrointestinal systems and how it may influence
the course of disease in cancer and AD alike. Finally, the emergence of the COVID-19 pandemic makes
research in the DS population a priority including for the development of potential therapies.
17. Dental & oral health
Issues with dental and oral health are very common in DS and often directly impact the quality of life.
There are many differences between individuals with DS and the general population [205]. Differences
include delayed eruption in babies and children, differences in eruption sequences for primary teeth,
microdontia, and hypodontia [206, 207]. People with DS may have large tongues (macroglossia), or
they may have an average size tongue but a small upper jaw that makes their tongue too large for their
mouth (relative macroglossia) causing difficulties with speech and breathing and contributing to OSA.
Small jaws and microdontia can cause tooth crowding and problems with spacing where the teeth of
the upper and lower jaws do not touch affecting the bite. Orthodontics may be able to improve some of
these issues, but this may present a particular challenge for children with DS. Finally, there are reports
that people with DS have a lower risk for cavities; however, much of that research was done when
people with DS lived in institutions and had very restricted diets. As such, more research is needed on
the caries prevalence in people with DS [208, 209].
People with DS may have an aggressive form of periodontitis characterized by rapid progression,
significant bacterial and inflammatory burden, and an onset as early as 6 years of age, which could
contribute to other systemic diseases as well [210–213]. However, studies have shown that periodontal
therapies may be effective [214]. It has been observed that in elderly cognitively normal people,
measures of periodontal destruction and periodontal dysbiosis is associated with brain amyloidosis
[215]. Given the high prevalence of both AD and periodontal disease in DS, more research is needed
to determine if periodontitis contributes to AD pathology [216].
Dental and oral health has a broad impact on overall health and quality of life. Thus, more research is
needed to understand the impact of dental and oral health in DS and the association with development,
sleep disorders, the immune system, and other common co-occurring conditions. This research could
lead to greater insights in the role of oral health on the overall health of people with DS and lead to
better treatment options.
18. Dental and oral health research gaps
The development and validation of cellular and animal models are needed to better understand the
characteristics of dental and oral health in individuals with DS. More research is needed to better
characterize the differences between DS and the general population in dental development and oral
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health to help inform medical guidelines. Furthermore, the impact of periodontal disease on the overall
health of individuals with DS is not well understood. DS mouse models should be employed to study
the possible association between periodontal disease and AD related pathology such as A␤ plaques,
neurofibrillary tangles, and neurodegeneration. Longitudinal and interventional studies should evaluate
the role of periodontal inflammation and bacterial dysbiosis on AD progression [217].
19. Alzheimer’s disease and aging
With improved care and extended longevity for people with DS, there has been an increase in
age-related disorders, especially AD, which typically occurs at an earlier age than that observed
in the general population [218] (Fig. 1). Indeed, compared to people without triplication of Chr21,
individuals with DS are at a markedly increased risk of developing AD. By age 40 years, ␤-amyloid
plaque pathology and neurofibrillary tangles are present in almost all people with full trisomy [219]. It
is estimated that the lifetime risk of AD is > 90% and that AD is the leading cause of death for adults
with DS [220, 221]. However, few adults with DS associated AD (DS-AD) or with other age-related
disorders receive appropriate care for a number of reasons. These include a shortfall of accepted and
validated standards for care, lack of practitioners trained to provide support and evaluate people with
DS-AD, inadequate data on the natural history of persons with DS-AD, lack of DS-specific diagnostic
and treatment approaches, lack of evidence of efficacy of existing treatments, and inadequate resources
for caregivers.
The reasons for the increased incidence of DS-AD are multifactorial but a primary driver is likely
related to genes on HSA21. Among the genes expressed on HSA21 is the gene for amyloid precursor
protein (APP). Overexpression of this protein due to trisomy leads to excess production of the toxic,
AD associated protein, ␤-amyloid. ␤-amyloid accumulates within senile plaques in the brain but also
can affect the blood vessels of the brain (cerebral amyloid angiopathy or CAA) [222]. Although most
people with DS are rarely affected by atherosclerosis and arteriosclerosis, which are two risk factors for
cerebrovascular pathology, there is significantly more CAA in DS than in people without DS or when
compared to older people with AD [223, 224]. Neuroinflammation may also show unique signatures
in the brains of people with DS, with features both common to and unique from sporadic AD [225].
Thus, there are multiple pathological events that occur either serially or in tandem to accelerate the
development of AD in people with DS.
Genetic, cell biology, cellular/animal models, and natural history studies have provided insight into
the aging process and the increased risk of dementia in individuals with DS. It is well known that the

Fig. 1. Prevalence of Early Dementia and AD by Age [218].
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brain undergoes accelerated aging changes in DS, but biological mechanisms for this have not been
fully explored. These studies suggest that increased expression of HSA21 genes induces many cellular
changes, including dysfunction of endosomal and lysosomal systems, composition of neurotrophic
signaling, increase in amyloid aggregation and cognitive defects, and alterations of microglia and
astrocyte function [219, 226–232]. Genome-wide association studies (GWAS) have identified 25 candidate DS-AD risk alleles. In small DS participant datasets, longitudinal telomere length changes
correlate with cognitive decline and accelerated epigenetic aging in DS is under investigation. Investigators probing the gut microbiome in people with DS have identified bacterial species that correlate
with Aberrant Behavior Checklist (ABC) scores [233]. In addition, novel biomarker methods including neuron-derived exosomes and more sensitive plasma-based assays allow early diagnostics and a
potential to better evaluate efficacy of interventions [234, 235].
Clinical phenotyping, biomarker development and validation in DS, and neuropathological diagnostic research have also progressed in recent years, enabling several clinical trials of potential AD
therapeutics in individuals with DS. In addition, animal and cellular models in development have
enabled exploration of therapeutic approaches, with early evidence that immune approaches may be
feasible [236]. Many collaborations and partnerships have been established in recent years to accelerate
research on DS-AD, including:
• Horizon 21, a multisite study in Europe recruiting a trial-ready cohort [237]
• The Alzheimer’s Biomarker Consortium-Down Syndrome (ABC-DS) – defining conversion to
dementia based on biomarkers [238]
• Longitudinal Investigation For the Enhancement of Down Syndrome Research (LIFE-DSR) – an
observational cohort study [239]
• Alzheimer’s Clinical Trials Consortium - Down Syndrome (ACTC-DS) is preparing to recruit a
trial-ready cohort [240]
• 3-Star study of the candidate vaccine, ACI-24 sponsored by AC Immune is nearing completion; AC Immune will also soon launch a Phase 2 trial of ␤-amyloid vaccine in adults with DS
[241]
20. Alzheimer’s disease and aging research gaps
More research support is needed to better understand the genetics and epigenetics of DS-AD. The
underlying mechanisms that lead to high APP expression in DS-AD pathogenesis is not well understood. For example, genetic and epigenetic regulation of APP expression remains largely unexplored
in people with DS. Epigenetic aging studies have been virtually unexplored in DS and could lead to
novel genetic pathways that are amenable to intervention. Another yet unexplored area is the influence
of specific microRNAs in the AD pathology. Chr. 21 contains several microRNAs, of which some have
been shown to affect AD pathology. There is a need to perform sampling at multiple time points to
evaluate trajectories across the lifespan. To explore the role of additional genetic AD risk factors, it will
also be valuable to compare GWAS hits in DS-AD to those from late onset AD (LOAD) including their
association with age of onset, cognitive decline, and variation in risk by sex or ethnicity. Other risk
factors also need research attention such as sex, race, ethnicity, the role of inflammation, the immune
system, and potential links to cerebrovascular pathology in DS-AD across the lifespan. There is a
need to further refine the amyloid/tau/neurodegeneration framework in DS for comparison to LOAD
and dominantly inherited AD and to identify where and how neuroinflammation and cerebrovascular
pathology contribute. The efficacy of treatments and care models in DS-AD are knowledge gaps. The
use of approved AD drugs in people with DS needs study to determine if these widely used drugs are
safe and/or appropriate for DS-AD. It is unknown if the therapeutic window of approved AD drugs is
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different for DS-AD as compared with LOAD. In addition, new care models need to be developed that
enhance the quality of life and longevity in individuals with DS-AD.
21. Community engagement
Community engagement is a continuum depending upon the level of collaboration between
researchers and the community yet is essential since members of the DS community can give meaningful insight into issues that are important to them across the lifespan. Community members should thus
be included in all aspects of research studies, starting with the design of the study, the determination
of inclusion and exclusion criteria, the selection of outcome measures, the recruitment of participants,
and the development of informed consent procedures. As a research study progresses, members of
the DS community should continue to be included in discussions of the progress of the study, interim
results, and communication protocols with research participants.
Community engagement research focuses on ensuring that the inclusion of community members
in studies achieves the goals of improving their understanding of the purpose of research, optimizes
recruitment for clinical studies, improves the reliability and validity of measurement tools, and improves
the translation of research into practice. The Community Engagement working group recommended
the need to communicate the message better so that people with DS understand the reason for the
research. They also called for the development of strategies to increase participation of people with
DS in clinical trials and to engage individuals with DS in the design of such trials.
22. Community engagement gaps
A recent survey of 256 individuals with DS found that 86% want new treatments and interventions,
but 64% never participated in research studies. In addition, for those that have participated in research
studies, direct interviews with individuals with DS and their caregivers found a lack of meaningful
engagement with them at each step of the research process. Increased efforts are needed to better understand the factors that lead to individuals with DS being significantly under-represented and oftentimes
excluded from research studies, including potential discrimination, rigid inclusion and exclusion criteria, low prioritization and limited community outreach and awareness. More infrastructure is needed
for outreach and information sharing and dissemination. In particular, new outreach approaches are
needed for the older adult community who tend to live outside the family unit in independent living,
groups homes and long-term care facilities.
23. General research needs
Each workgroup identified research needs for their specific focus area and many of these research
gaps have been highlighted above. However, the workgroups also identified areas that represent clear
DS research needs that cross multiple disciplines. The table below summarizes eight areas of overall research need that, if funded, would significantly improve the understanding of DS and lead to
improvements in treatments and quality of life. The eight overall topic areas are clinical and genetic
phenotyping, cellular and animal models of DS, longitudinal studies, randomized controlled trials
in the DS population, centralized biorepository, open access centralized DS data, research training
for clinicians and scientists, and research inclusion. The workgroups also developed a comprehensive list of recommendations in response to the DS RFI. The full list of recommendations can be
found at: https://www.nih.gov/sites/default/files/research-training/initiatives/include/down-syndromeRFI-responses-combined.pdf.

116

J.A. Hendrix et al. / Opportunities, barriers, and recommendations in Down syndrome research
Table 1
Overall Priority Recommendations for DS Research

Recommendations

Milestones

Clinical and Genetic Phenotyping
Establish a panel of DS experts to
define clinical and genetic phenotypes

- Define DS phenotypes for clinical trials from existing data
- Develop clinical guidelines and personalized medicine approaches unique
to DS
- Identify changes related to stage of life and aging including inflammation
and metabolism

Conduct an “All of US” DS sub-study
of 5000 participants

- Use GWAS and clinical data to help define DS phenotypes

Expand genetic and epigenetic
profiling beyond Chr21

- Elucidate complex gene-network effects and incorporate knowledge from
non-DS populations

Gather more unbiased -Omics data

- Global and tissue specific metabolomics data to help establish metabolic
phenotypes and to discover new biomarkers of metabolic disease.
- Lipidomics data to better understand the risk of diabetes and obesity in DS
- Comprehensive ‘omics’ in brain samples to define genome, epigenome,
metabolome, transcriptome and proteome
- Microbiome (i.e. gut, oral) to better understand the potential associations
of the microbiome to diseases common in DS

Expand the DS Connect portal and
collect DS to compare with data from:

- the general population
- people with intellectual disabilities but without DS
- siblings of people with DS who do not have DS themselves
- people with autosomal dominant AD

Cellular and animal models of DS
Current understanding of DS
neurobiology is derived largely from
mouse studies (Ts65Dn, Tc1)
including anatomical and behavioral
analyses of organismal brain
development. Develop and validate
mouse models that better translate to
characteristics in individuals with DS

- Support for new in vivo models that will better represent HSA21 genetic
changes are needed.
- Determine the extent of correspondence between findings in models and
human biomarkers.
- Perform comparative phenotyping including aging and lifespan of all DS
mouse models.
- Comprehensive ‘omics’ including the metabolome in all DS mouse
models (including aging studies) are needed to better characterize these
models.
- Define and compare genetics, mechanisms and significance of
dysregulated endosomes, exosomes, autophagosome, and proteostasis in
all DS mouse models.
- Map pathogenesis pathways in the DS mouse models, testing for the
contribution of individual dysregulated genes.
- Design new treatment paradigms and pathways for testing in DS mouse
models (dose-response/toxicity studies).

Support new models (including in
mouse, rat, or non-human primate)
that best model DS

- Develop animal models that can reflect the structural changes in human
DS brain and other differences such as the immune system.

Develop novel cellular models of DS

- Support development of human DS cellular models (e.g. induced
pluripotent stem cell (iPSC) neuronal cultures), exploring variation by
both sex and genetic ancestry.
- Develop the use of human iPSC models for more organ systems and
pathways affected in DS.
(Continued)
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Table 1
(Continued)

Recommendations

Milestones

Increase collaboration between bench
to bedside researchers to share results
and enhance translational research in
DS.

- Ensure that clinical scientists have the tools to implement advances from
bench research, and that bench discoveries are important to clinical
researchers.
- Identify gaps and discrepancies between basic research and clinical
observations and address them.
- Facilitate collaborations between neuropathologists and DS clinicians to
assess translational relevance of model systems and biomarkers to DS
neurobiology.
- Explore links between cellular phenotypes/mechanisms in DS mouse
models with clinical findings including fluid biomarkers.
- Translate insights from mouse models to clinic to inform possible
treatments and novel trial designs.

Longitudinal Studies
Support studies in the DS population
over the life course and help to define
clinical phenotypes to inform future
research including clinical trials.

- Expand and extend on-going longitudinal studies to keep these important
cohorts generating valuable data from more people for more years.
- Conduct longitudinal studies across all age groups including adolescents
and young adults.
- Facilitate international communication and data sharing of between
research studies – e.g. ABC-DS/Horizon 21.

Within existing and new longitudinal
cohorts, support efforts to more
clearly define and chart trajectory of:

- Cognitive function.
- Behavioral assessments.
- Include participant and caregiver reported outcomes.
- Include biomarkers as available (imaging, fluid and genetic)
- Sex effects.
- Contribution of comorbid conditions such as thyroid function, heart disease,
obesity, metabolic disorders, autoimmune disorders, OSA to health.
- Environmental influences such as education, home setting, work,
medications, and use of supplements.
- Incorporate new technology, data, and/or samples as appropriate. For
example, as new low-cost genome sequencing technology becomes
available, studies could add genomics to existing cohorts.

Establish new DS cohorts with
specific goals

Develop partial trisomy and mosaic DS cohorts, including bio-samples,
iPSC lines and brain banks.

Randomized Controlled Trials (RCT) in the DS Population
Expand support for drug and devise
RCT’s across the DS lifespan

- Build and sustain trial-ready DS cohorts across the lifespan.
- Assess benefits across the lifespan to improve cognitive outcomes in
childhood and delay declines in adulthood
- Determine the age when an intervention will have the most benefit for
people with DS.
- Support for more drug repurposing trials in DS where target and
mechanistic rationales exist.

Support for RCT’s on the efficacy of
life-style interventions in the DS
population across the lifespan.
Explore outcomes of physical fitness,
health, behavior, cognition, and
development.

- Test interventions that effectively increase physical activity and reduce
sedentary behavior.
- Develop effective lifestyle interventions that foster healthy behaviors.
- Test interventions that reduce obesity and improve overall health outcomes.
- Test the efficacy of technologies (i.e. animal-assisted therapies, digital,
wearable technology) to promote healthy behaviors.
(Continued)
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(Continued)

Recommendations

Milestones

Support research to enable RCT’s in
DS.

- Find an appropriate control population with which to compare DS
participants (related to BMI, BP, activity levels, intellectual disability, etc.).
- Conduct studies with large enough sample sizes to produce statistical
power and significance to generalize the results to the larger DS population.
- Explore differences in drug metabolism (pharmacokinetics /
pharmacodynamics) and drug safety in both children and adults with DS
compared with the general population for experimental drug candidates
and with FDA-approved drugs.

Establish the safety and efficacy of
FDA approved drugs in both children
and adults with DS via RCT’s.

- Conduct RTC’s in drugs commonly used to treat mood disorders, cognitive
deficits, autoimmune disorders, and other manifestations.
- Document side effect, safety and efficacy data including behavioral and
cognitive effects of approved drugs.
- Improve assessment and management of side effects during treatment. (i.e.
pain/nausea during cancer therapy).

Expand support for clinical trial
recruitment.

- Support efforts to inform participants and caregivers of the value of
research activities and encourage trial participation.
- Build infrastructure to facilitate enrollment in clinical trials with
disease-specific or condition-specific sub-groups.
- Expand expertise in recruiting specific age ranges particularly for adults
and underrepresented groups.
- Expand DS Connect or establish other approaches to support clinical trial
recruitment.

Expand support and training in the
conduct of DS RCT’s

- Provide training to sites that may not have clinical research experience or
DS clinical experience.

Develop and disseminate
methodology for studying
cognitive/behavior outcome measures
in the context of large, multi-site
trials.

- Develop or employ outcome measures that have demonstrable clinical
utility (i.e. predict real-world changes in behavior, cognition, and/or
adaptive skill independence).
- Identify the participants that may be appropriate for a clinical trial given
the selected outcome measures.

Expand clinical trial data sharing

- Harmonize DS clinical protocols with between networks in the US and
internationally to enable more meaningful data sharing.

Centralized Biorepository
Expand support for centralized (or
virtual) biorepository of DS samples
collected across the life span.

- Expand support for brain banks and fluid biobanks from well-characterized
participants with clinical, behavioral, and functional data and with
REDCap accessibility.
- Establish a robust plan for banking of cells, plasma, serum, CSF, and brains
either centrally or tracked via a virtual repository.
- Produce and store specific cells types such as peripheral blood mononuclear
cells (PBMC’s), iPSC’s and exosomes (brain derived and peripheral).
- Establish a fair and equitable process for reviewing and approving request
for access to samples.
- The collection and storage of the samples should be standardized using
established “best practices”.
- Integrate biobanking efforts with existing “best practices” for genomic
data-sharing, including file formats, storage/hosting solutions, and
versioning protocols.
(Continued)
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Table 1
(Continued)

Recommendations

Milestones
- Prioritize (epi)genome-wide profiling over candidate-gene profiling to
address diminishing costs of throughput while preserving scarce and
highly valuable tissue samples.
- Integrate the biorepository data with DS Connect to increase the value of
both resources.

Open Access Centralized DS Data
Establish a single network for DS
data.

- Continue efforts to establish data standards and data sharing in the DS
research community.
- Establish a centralized data repository or federated network where
researcher can go as a “one-stop-shop” for DS data.
- The centralized data repository mentioned above could include information
on access to biorepositories and access to well-characterized sample.
- Support long standing DS clinics to digitize their clinical data into an open
access, searchable format
- Support the creation of curated data sets that included assessment, survey,
and transcription DS data leading to large data sets that support the use of
computational modeling.

Research Training for Clinicians and Scientists
Support training clinical trials and
clinical neuroscience in DS.

- Provide training for clinicians and researchers in DS who are both
established and early in their career to attract them to the field.
- Support the development of Master Clinics for Adults with DS (MCADS)
that operate on a hub and spoke model to provide adults access to expertise
across the US, train physicians in DS medical care and that enable clinical
trial readiness activities.
- Encourage interdisciplinary research collaboration and support cross
disciplinary training with a focus on DS.

Research Inclusion
Expand the inclusion of individuals
with DS who have been significantly
under-represented and oftentimes
excluded from all sorts of research.

- Develop strategies to increase the participation of people with DS in
non-DS focused research.
- Develop strategies to increase participation in research focused on
DS-specific priorities of people with DS.
- Increase the participation of people with DS in the design of studies for
both DS and non-DS specific research.

24. Conclusion
While it is true that the life expectancy for people with DS has increased significantly in recent
decades thanks to advances in medical care, this review clearly demonstrates that many scientific gaps
remain that prevent further advances in the discovery of new treatments and improvements in quality
of life. These research recommendations were developed specifically in response to the NIH RFI and
it is the hope of the coauthors that the NIH will not only include the recommendations submitted
and published here in their Research Plan on Down Syndrome, but also provide sufficient funding
for implementation. The coauthors also recognize that, for these recommendations to achieve their
desired result, a coordinated approach with other funders of research, including other U.S. government
agencies, and non-government organizations is needed. In addition, it is hoped that this paper will
serve as a call to action for policymakers and the DS community around a focused and comprehensive
national Down syndrome research strategy.
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Dedication
This paper is dedicated to the memory of Dr. Angelika Amon who was a leader in Down syndrome
research and who made significant contributions to this review.
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